Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023

On November 28, 2023 Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, reported that it will host a virtual KOL event to discuss new data from the VISTA-101 clinical trial of KVA12123 in patients with advanced solid tumors (Press release, Kineta, NOV 28, 2023, View Source;utm_medium=rss&utm_campaign=kineta-to-host-kol-event-to-review-new-data-from-vista-101-clinical-trial-of-kva12123-in-patients-with-advanced-solid-tumors-on-december-5-2023 [SID1234638007]). Details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
Tuesday, December 5, 2023 at 2:00 P.M. Eastern Time
To register, click here.

The event will feature presentations from two key opinion leaders in immuno-oncology:

Michael A. Curran, Ph.D., Associate Professor at MD Anderson Cancer Center Department of Immunology, who will discuss key challenges with current cancer therapies and the potential for VISTA blocking immunotherapy to reverse immunosuppression in the tumor microenvironment (TME) and drive anti-tumor activity.
Evan Y. Yu, M.D., Professor and Medical Oncology Section Head at Fred Hutchinson Cancer Center, who will join Kineta leadership to discuss immuno-oncology clinical trials and review the new positive monotherapy data from the ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, the company’s VISTA blocking immunotherapy, in patients with advanced solid tumors.
A live question and answer session will follow the formal presentations.